Neurologic Disease Research at UC Davis Contributes to First Treatment Specifically Approved for Postpartum Depression
Michael Rogawski conducted lab and clinical research on the neuro-steroid (SACRAMENTO) — Sage Therapeutics announced March 19 the U.S. Food and Drug Administration’s approval of its product, Zulresso™ (brexanolone) injection, for the treatment of postpartum depression in women. Initial development of an intravenous formulation of allopregnanolone (also known as brexanolone) and first-in-human clinical studies were conducted […]

